Compare CNS & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNS | AMLX |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.8B |
| IPO Year | 2004 | 2021 |
| Metric | CNS | AMLX |
|---|---|---|
| Price | $69.86 | $27.76 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $69.33 | $43.00 |
| AVG Volume (30 Days) | 202.8K | ★ 1.3M |
| Earning Date | 10-15-2026 | 11-05-2026 |
| Dividend Yield | ★ 3.76% | N/A |
| EPS Growth | N/A | ★ 65.46 |
| EPS | ★ 2.58 | N/A |
| Revenue | ★ $427,536,000.00 | $380,786,000.00 |
| Revenue This Year | $9.41 | N/A |
| Revenue Next Year | $5.94 | $56,076.69 |
| P/E Ratio | $27.66 | ★ N/A |
| Revenue Growth | 4.07 | ★ 1612.94 |
| 52 Week Low | $58.39 | $10.83 |
| 52 Week High | $86.56 | $41.14 |
| Indicator | CNS | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 42.05 | 45.03 |
| Support Level | $69.20 | $26.49 |
| Resistance Level | $73.34 | $29.30 |
| Average True Range (ATR) | 2.38 | 1.81 |
| MACD | -0.18 | 0.11 |
| Stochastic Oscillator | 6.30 | 9.33 |
Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests primarily in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for nearly two-thirds of its $102.5 billion in managed assets at the end of July 2026. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (25%) of its managed assets (base management fees) from institutional clients, 48% (55%) from open-end funds, and 13% (20%) from closed-end funds.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.